EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)Open Access · CC BY 4.0

Opicapone to Treat Early Wearing‐off in Parkinson's Disease Patients: The Korean ADOPTION Trial

Jee-Young Lee iD, Hyeo-Il Ma iD, Joaquim J Ferreira iD, José-Francisco Rocha iD, Young Hee Sung iD, In-Uk Song iD, Tae-Beom Ahn iD, Do Young Kwon iD, Sang-Myung Cheon iD, Jong-Min Kim iD, Chong Sik Lee iD, Phil Hyu Lee iD und 10 weitere

Movement Disorders Clinical Practice · 2024

DOI: 10.1002/mdc3.14030 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders Clinical Practice, 2024. Verfasst von Jee-Young Lee und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, SMG-SNU Boramae Medical Center, Seoul, Korea. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Antiparkinson Agents, Oxadiazoles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Laboratórios Bial - Bial - Portela & Cª, S.A, Portugal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Increasing levodopa (L‐dopa)/dopa decarboxylase inhibitor (DDCI) daily dose or adding a catechol‐O‐methyltransferase (COMT) inhibitor to levodopa/DDCI therapy are strategies used to manage wearing‐off symptoms in Parkinson's disease (PD) patients.

Objectives

To evaluate the COMT inhibitor opicapone versus an additional dose of levodopa to treat early wearing‐off in PD patients.

Methods

ADOPTION was a randomized, parallel‐group, open‐label, Phase 4 study conducted in Korea. At baseline, eligible patients were randomized (1:1) to opicapone 50 mg (n = 87) or L‐dopa 100 mg (n = 81) (added to current L‐dopa/DDCI therapy) for 4 weeks. The main efficacy endpoint was change from baseline to end of study in absolute off time. Other endpoints included changes in on time, in Movement Disorder Society‐Unified Parkinson's Disease Rating Scale and 8‐item PD Questionnaire scores, and the Clinical and Patient Global Impression of Improvement/Change.

Results

The adjusted mean in absolute off time was significantly greater for opicapone 50 mg than for L‐dopa 100 mg (−62.1 vs. −16.7 minutes; P = 0.0015). Opicapone‐treated patients also reported a greater reduction in the percentage of off time ( P = 0.0015), a greater increase in absolute on time ( P = 0.0338) and a greater increase in the percentage of on time ( P = 0.0015). There were no significant differences in other secondary endpoints. The L‐dopa equivalent daily dose was significantly higher in the opicapone group (750.9 vs. 690.0 mg; P = 0.0247), when a 0.5 conversion factor is applied.

Conclusions

Opicapone 50 mg was more effective than an additional 100 mg L‐dopa dose at decreasing off time in patients with PD and early wearing‐off.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLevodopaAntiparkinson AgentsOxadiazolesHumansMaleFemaleAgedMiddle AgedCatechol O-Methyltransferase InhibitorsRepublic of KoreaTreatment Outcome

Stichwörter der Autor:innen

Parkinson's diseaselevodopaopicaponewearing off

Substanzen

opicaponeLevodopaAntiparkinson AgentsOxadiazolesCatechol O-Methyltransferase Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, SMG-SNU Boramae Medical Center, Seoul, Korea.
  • Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, Korea.
  • IMM - Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • CNS - Campus Neurológico, Torres Vedras, Portugal.
  • BIAL - Portela & Ca S.A, Coronado, Portugal.
  • Gachon University Gil Medical Center, Incheon, Korea.

ORCID-Profile: Jee-Young Lee, Hyeo-Il Ma, Joaquim J Ferreira, José-Francisco Rocha, Young Hee Sung, In-Uk Song, Tae-Beom Ahn, Do Young Kwon, Sang-Myung Cheon, Jong-Min Kim, Chong Sik Lee, Phil Hyu Lee, Jeong-Ho Park, Jae-Hyeok Lee, Mee Young Park, Sang Jin Kim, Jong Sam Baik, Seong-Min Choi, Hae-Won Shin, Ho-Won Lee, Suk Yun Kang, Beomseok Jeon

Förderung

  • Laboratórios Bial - Bial - Portela & Cª, S.A, Portugal

Zitieren

APA

Lee, J. Y., Ma, H. I., Ferreira, J. J., Rocha, J. F., Sung, Y. H., Song, I. U., Ahn, T. B., Kwon, D. Y., Cheon, S. M., Kim, J. M., Lee, C. S., Lee, P. H., Park, J. H., Lee, J. H., Park, M. Y., Kim, S. J., Baik, J. S., Choi, S. M., Shin, H. W., …, & Jeon, B. (2024). Opicapone to Treat Early Wearing‐off in Parkinson's Disease Patients: The Korean ADOPTION Trial. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14030

Vancouver

Lee JY, Ma HI, Ferreira JJ, Rocha JF, Sung YH, Song IU, et al. Opicapone to Treat Early Wearing‐off in Parkinson's Disease Patients: The Korean ADOPTION Trial. Movement Disorders Clinical Practice. 2024. doi:10.1002/mdc3.14030

BibTeX
@article{Lee2024,
  author = {Lee, Jee-Young and Ma, Hyeo-Il and Ferreira, Joaquim J and Rocha, José-Francisco and Sung, Young Hee and Song, In-Uk and Ahn, Tae-Beom and Kwon, Do Young and Cheon, Sang-Myung and Kim, Jong-Min and Lee, Chong Sik and Lee, Phil Hyu and Park, Jeong-Ho and Lee, Jae-Hyeok and Park, Mee Young and Kim, Sang Jin and Baik, Jong Sam and Choi, Seong-Min and Shin, Hae-Won and Lee, Ho-Won and Kang, Suk Yun and Jeon, Beomseok},
  title = {Opicapone to Treat Early Wearing‐off in Parkinson's Disease Patients: The Korean ADOPTION Trial},
  journal = {Movement Disorders Clinical Practice},
  year = {2024},
  doi = {10.1002/mdc3.14030}
}
Kostenlos starten →